Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs LyondellBasell Industries NV — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while LyondellBasell Industries NV trades at $57.5 (market cap $18.19B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.2× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays a 7.31% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LYB | |
|---|---|---|
Market Cap | $39.89B | $18.19B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $82.38 |
52-Week Low | $278.09 | $42.28 |
Enterprise Value | $38.15B | $29.81B |
Dividend Yield | — | 7.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
LYB trades at $56.36, up 1.74% today, with a bearish technical signal and mixed earnings history including a recent Q1 2026 beat. The company shows declining revenue and negative net income margins, though it maintains positive operating cash flow and recently announced a partnership for recycled-content packaging with Mondelez. Analyst consensus is a Buy with a $73.11 price target, indicating potential upside from current levels.
Outlook remains cautious due to profitability challenges and elevated debt, but cost-cutting and strategic shifts toward higher-margin polymers offer recovery potential. Key risks include persistent margin pressure and macroeconomic sensitivity, while institutional sentiment is divided between growth optimism and fundamental concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
